Immunoadsorption Versus Immunoglobulins for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Launched by UNIVERSITY OF ULM · May 5, 2021

Keywords

ClinConnect Summary

This clinical trial is studying two different treatments for a condition called Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), which affects the nerves and can cause weakness and numbness. The trial is comparing the safety and effectiveness of a treatment called immunoadsorption to another treatment called immunoglobulins in patients who have not responded well to steroids. If you or a loved one has been diagnosed with CIDP and have had the disease for three years or less, you may be eligible to participate in this study.

To join, participants must be at least 18 years old, and have already tried a steroid treatment called methyl-prednisolone without enough improvement or experienced significant side effects. Those with certain infections or specific health conditions may not be eligible. If you participate, you'll receive one of the two treatments and be closely monitored by the study team. This is a great opportunity to contribute to research that could help improve treatments for CIDP in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Diagnosis of possible, probable, or definite CIDP (typical or atypical) according to European Federation of Neurological Societies (EFNS) guidelines
• • Disease duration of 3 years or less
• • Age 18 years or above
• • Previous treatment with methyl-prednisolone and insufficient therapeutic response as judged by the treating physician, or contraindications against methyl-prednisolone, or clinically significant side effects under methyl-prednisolone therapy as judged by the treating physician
• Exclusion Criteria:
• • Clinical or laboratory evidence of manifest systemic infection, i.e., C-reactive protein (CRP) above 20 mg/l, or evidence of nitrite-positive urinary tract infection
• • Intake of angiotensin converting enzyme inhibitor within 1 week before first treatment
• • immunoglobulin A deficiency
• • Other contraindications against immunoadsorption or intravenous immunoglobulins